A Randomized, Placebo Controlled, Partially Blinded Phase II Study to Evaluate Safety, Immunogenicity, and Prevention of Infection With Mycobacterium Tuberculosis of AERAS-404 and BCG Revaccination in Healthy Adolescents
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2017
At a glance
- Drugs H4IC (Primary) ; BCG vaccine
- Indications Tuberculosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Aeras
- 07 Jun 2017 Biomarkers information updated
- 23 Jan 2017 Planned End Date changed from 1 Sep 2016 to 1 Dec 2017.
- 23 Jan 2017 Planned primary completion date changed from 1 Sep 2016 to 1 Sep 2017.